Strep Throat in Children: Antibiotic Choice & Dosing Guide
TL;DR
- Strep throat antibiotic children first-line therapy: amoxicillin 50 mg/kg/day (max 1 g) for 10 days, per IDSA and AAP guidelines.
- Penicillin V remains an equivalent alternative but requires multiple daily doses and has a less palatable liquid formulation.
- Children with confirmed penicillin allergy can receive cephalexin (non-anaphylactic) or azithromycin/clindamycin (anaphylactic history).
- Never treat viral pharyngitis with antibiotics. A positive rapid antigen detection test (RADT) or throat culture is required before prescribing.
- Complete the full 10-day course even if symptoms resolve in 24–48 hours — shortened courses increase rheumatic fever risk.
What Is Strep Throat and Why Does It Matter in Children?
Strep throat — acute pharyngitis caused by group A Streptococcus (GAS, Streptococcus pyogenes) — is one of the most common bacterial infections in childhood. It accounts for 20–30% of pharyngitis cases in children aged 5–15 years, compared with only 5–15% in adults. Children under 3 rarely develop classic strep pharyngitis, though they may present with streptococcal nasopharyngitis or fever without localizing signs.
The clinical significance of GAS pharyngitis extends beyond the sore throat itself. Untreated or inadequately treated infection carries the risk of suppurative complications (peritonsillar abscess, retropharyngeal abscess, cervical lymphadenitis) and non-suppurative sequelae — most importantly acute rheumatic fever (ARF) and post-streptococcal glomerulonephritis. While ARF incidence has declined substantially in high-income countries, it remains a leading cause of acquired heart disease in children globally. Antibiotic therapy for confirmed GAS pharyngitis is the only proven strategy for primary prevention of ARF.
The challenge for clinicians and parents alike is distinguishing bacterial from viral pharyngitis — a distinction that determines whether a strep throat antibiotic prescription is appropriate or harmful.
Diagnosis: When to Test, When to Treat
The Infectious Diseases Society of America (IDSA) 2012 guideline — the most widely referenced North American standard — is explicit: clinical features alone cannot reliably distinguish GAS from viral pharyngitis. The modified Centor (McIsaac) score helps stratify risk but should not replace microbiological confirmation in children.
Modified Centor (McIsaac) Criteria
| Criterion | Points |
|---|---|
| Temperature >38°C (100.4°F) | +1 |
| Absence of cough | +1 |
| Tender anterior cervical lymphadenopathy | +1 |
| Tonsillar swelling or exudate | +1 |
| Age 3–14 years | +1 |
| Age 15–44 years | 0 |
| Age ≥45 years | −1 |
Interpretation for children: A score of ≥2 warrants testing (RADT ± backup culture). A score of 0–1 generally does not require testing unless there are epidemiological risk factors (e.g., household contact with confirmed GAS).
IDSA Testing Recommendations for Children
- Perform RADT on all children aged ≥3 years with signs and symptoms suggestive of GAS pharyngitis.
- Confirm negative RADT with throat culture in children and adolescents (RADT sensitivity is approximately 70–90%; culture remains the gold standard).
- Do not test children <3 years routinely unless specific risk factors are present (ARF in a household contact, high community prevalence).
- Do not test asymptomatic children — positive results likely reflect carrier state rather than acute infection.
Key takeaway: Antibiotics should only be prescribed when GAS is confirmed by RADT or culture. Empirical treatment based on clinical appearance alone leads to significant antibiotic overuse.
When NOT to Treat: Viral Pharyngitis and the Carrier State
Two scenarios regularly lead to inappropriate antibiotic prescribing in children, and both deserve emphasis.
Viral Pharyngitis
The majority of sore throats in children are viral. Rhinovirus, adenovirus, Epstein-Barr virus (EBV), influenza, and enteroviruses collectively cause 70–80% of childhood pharyngitis. Classic viral features — cough, rhinorrhea, conjunctivitis, hoarseness, oral ulcers, diarrhea — should steer clinicians away from testing for GAS. Antibiotics provide no benefit in viral pharyngitis and expose children to unnecessary adverse effects, including diarrhea, allergic reactions, and contribution to antimicrobial resistance.
The GAS Carrier State
An estimated 5–20% of school-age children carry GAS in their pharynx without active infection. These carriers are at very low risk for rheumatic fever and are unlikely to transmit GAS to contacts. The IDSA guideline explicitly recommends against attempting to identify or treat carriers. Practical implications:
- A child with viral symptoms who tests positive for GAS on RADT may be a carrier with a concurrent viral illness, not a child with bacterial pharyngitis.
- Post-treatment test-of-cure cultures are not recommended for asymptomatic children, as positive results usually reflect the carrier state.
- Eradication of the carrier state is generally not pursued unless there is a personal or family history of ARF, or during community outbreaks of rheumatic fever or invasive GAS disease.
First-Line Antibiotics: Amoxicillin and Penicillin V
The IDSA (2012), AAP Red Book, and the American Heart Association (AHA) all agree on first-line therapy: penicillin or amoxicillin for 10 days. GAS remains universally susceptible to penicillins — no penicillin-resistant GAS isolate has ever been confirmed clinically. This makes strep pharyngitis a pharmacological rarity: a common infection for which resistance to first-line therapy is essentially nonexistent.
Why Amoxicillin Over Penicillin V?
In practice, amoxicillin has become the preferred first-line agent for children with strep throat, for several practical reasons:
- Better palatability — amoxicillin suspension is significantly better tasting than penicillin V liquid, a non-trivial factor in pediatric adherence.
- Once-daily dosing option — amoxicillin 50 mg/kg once daily has demonstrated equivalent efficacy to divided-dose regimens in clinical trials, simplifying administration.
- Higher bioavailability — amoxicillin achieves approximately 70–80% oral bioavailability compared with 25–30% for penicillin V.
- Equivalent efficacy and safety — head-to-head comparisons show no clinically meaningful differences in bacteriological or clinical cure rates.
Penicillin V remains a valid first-line choice, particularly for older children and adolescents who can swallow tablets, and in settings where cost is a primary concern.
Evidence-Based Antibiotic Options: Comparison Table
The following table summarizes antibiotics recommended by the IDSA 2012 guideline for treatment of GAS pharyngitis in children, including alternatives for penicillin-allergic patients.
| Antibiotic | Indication | Pediatric Dose | Frequency | Duration | Key Notes |
|---|---|---|---|---|---|
| Amoxicillin | First-line | 50 mg/kg/day (max 1000 mg) | Once daily or divided BID | 10 days | Best palatability; preferred in young children |
| Penicillin V | First-line | ≤27 kg: 250 mg; >27 kg: 500 mg | BID–TID | 10 days | Universally effective; poor-tasting liquid |
| Penicillin G benzathine (IM) | First-line (adherence concern) | ≤27 kg: 600,000 U; >27 kg: 1.2 million U | Single dose | One-time | Guaranteed adherence; painful injection |
| Cephalexin | Penicillin allergy (non-anaphylactic) | 20 mg/kg/dose (max 500 mg) | BID | 10 days | ~2% cross-reactivity with penicillin; avoid if anaphylaxis history |
| Cefadroxil | Penicillin allergy (non-anaphylactic) | 30 mg/kg/day (max 1000 mg) | Once daily | 10 days | Convenient dosing; same cross-reactivity caution |
| Azithromycin | Penicillin allergy (anaphylactic) | Day 1: 12 mg/kg (max 500 mg); Days 2–5: 6 mg/kg (max 250 mg) | Once daily | 5 days | ~5–8% GAS resistance in some regions; check local antibiogram |
| Clindamycin | Penicillin allergy (anaphylactic) | 7 mg/kg/dose (max 300 mg) | TID | 10 days | No cross-reactivity; C. difficile risk; useful for recurrent GAS |
Detailed Dosing and Practical Administration
Amoxicillin — The Workhorse
Amoxicillin is available as 125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL, and 400 mg/5 mL oral suspensions, as well as chewable tablets and capsules. The dosing is weight-based:
50 mg/kg once daily (max 1000 mg/day) for 10 days, or equivalently, 25 mg/kg twice daily (max 500 mg/dose).
| Child Weight | Once Daily Dose | Twice Daily Dose (per dose) | Suggested Formulation |
|---|---|---|---|
| 10 kg (22 lb) | 500 mg | 250 mg | 250 mg/5 mL: give 10 mL QD or 5 mL BID |
| 15 kg (33 lb) | 750 mg | 375 mg | 400 mg/5 mL: give 9.4 mL QD or 4.7 mL BID |
| 20 kg (44 lb) | 1000 mg | 500 mg | 400 mg/5 mL: give 12.5 mL QD or 6.25 mL BID |
| 25 kg (55 lb) | 1000 mg (max) | 500 mg | Capsules or chewable tablets if age-appropriate |
| ≥30 kg (66 lb) | 1000 mg (max) | 500 mg | Adult capsule/tablet dosing |
Practical tips for parents:
- Amoxicillin suspension should be refrigerated after reconstitution and used within 14 days.
- The medication can be mixed with a small amount of milk, formula, or juice immediately before administration if the child resists the taste.
- Complete the full 10-day course. Symptoms typically improve within 48–72 hours, but premature discontinuation increases the risk of treatment failure, relapse, and — most critically — rheumatic fever.
Penicillin G Benzathine — The One-Shot Option
For families where adherence to a 10-day oral course is a genuine concern — and the clinician and family agree — a single intramuscular injection of penicillin G benzathine provides complete therapy. This option is particularly relevant in populations with high ARF prevalence. The injection is painful, and use of lidocaine as a diluent or co-injection is common practice to reduce discomfort.
Managing Penicillin Allergy in Children
Reported penicillin allergy is common in pediatric practice — parents frequently label their children as "allergic" based on non-specific rashes that occurred during a prior course of amoxicillin. Fewer than 10% of patients with a reported penicillin allergy have a true IgE-mediated allergy, and the rate decreases over time. When feasible, penicillin allergy testing (skin testing or graded oral challenge) can safely de-label many of these children and restore access to first-line therapy.
When allergy status has not been formally evaluated, the IDSA recommends stratifying management by the nature of the reported reaction:
Non-Anaphylactic Reaction (Rash, Mild Symptoms)
First-generation cephalosporins — cephalexin or cefadroxil — are recommended. The cross-reactivity rate between penicillins and first-generation cephalosporins is estimated at 1–2%, far lower than the historically quoted 10% figure. These agents are well tolerated and demonstrate excellent GAS eradication rates.
Anaphylactic or Severe Reaction (Urticaria, Angioedema, Bronchospasm, Anaphylaxis)
Cephalosporins should be avoided in children with a history of anaphylaxis, severe urticaria, or other immediate-type hypersensitivity to penicillin. Options include:
- Azithromycin — convenient 5-day course, once-daily dosing. However, macrolide resistance among GAS isolates has been increasing in some regions (reported at 5–15% in parts of Europe and Asia). Local antibiogram data should guide this choice.
- Clindamycin — effective and not cross-reactive with penicillins. The main drawback is TID dosing for 10 days and an association with Clostridioides difficile infection, though the absolute risk in otherwise healthy children is low.
Side Effects and Monitoring
Common Adverse Effects by Agent
Amoxicillin / Penicillin V:
- Gastrointestinal upset (nausea, diarrhea) in approximately 5–10% of children.
- Non-allergic rash — particularly the characteristic maculopapular "amoxicillin rash," which occurs in up to 5–10% of children and is more common in those with concurrent EBV infection (infectious mononucleosis). This is not a true allergy but is frequently mislabeled as one.
- True allergic reactions (urticaria, anaphylaxis) — uncommon (<2%).
Cephalexin:
- Similar GI side-effect profile to amoxicillin.
- Hypersensitivity reactions are possible but uncommon.
Azithromycin:
- GI upset (abdominal pain, nausea, diarrhea) is the most common adverse effect.
- QT prolongation — clinically significant arrhythmia is exceedingly rare in otherwise healthy children but warrants caution in those with known QT prolongation or concomitant QT-prolonging medications.
Clindamycin:
- Diarrhea (up to 20% of patients).
- C. difficile colitis — rare in healthy children but should be considered if watery diarrhea develops during or after treatment.
- Dysgeusia (unpleasant taste) with the oral solution.
When to Seek Re-Evaluation
Children on appropriate antibiotic therapy should show clinical improvement within 48–72 hours. If fever and severe pharyngeal symptoms persist beyond this window, the clinician should consider:
- Non-adherence to the prescribed regimen.
- Suppurative complication (peritonsillar abscess).
- Alternative diagnosis (e.g., EBV mononucleosis, which may present similarly and cause worsening with amoxicillin rash).
- Rarely, co-infection or an unusual pathogen.
Special Populations
Children Under 3 Years
Classic GAS pharyngitis is uncommon below age 3. Young children with GAS exposure more often develop streptococcal nasopharyngitis — featuring mucopurulent rhinitis, low-grade fever, and irritability — rather than acute tonsillopharyngitis. The IDSA does not recommend routine RADT or culture in this age group unless there is a specific indication (e.g., household contact with ARF history, daycare outbreak). When treatment is indicated, amoxicillin dosing follows the same weight-based approach.
Recurrent Strep Throat
Some children experience multiple episodes of confirmed GAS pharyngitis per year. The IDSA suggests the following approach:
- Confirm each episode microbiologically — a positive test during an acute episode in a known carrier may not represent true reinfection.
- Consider alternative antibiotics for recurrent episodes — clindamycin or amoxicillin-clavulanate may be more effective than amoxicillin alone for eradication in recurrent cases, possibly because of beta-lactamase-producing co-pathogens that shield GAS.
- Tonsillectomy may be considered in children meeting Paradise criteria (≥7 episodes in 1 year, ≥5/year for 2 years, or ≥3/year for 3 years), though the decision involves weighing surgical risks against the likely natural decline in episode frequency over time.
Immunocompromised Children
Children receiving immunosuppressive therapy or with primary immunodeficiency should be managed with standard GAS treatment protocols. There is no evidence supporting prolonged or broader-spectrum antibiotic therapy for GAS pharyngitis in this population. However, vigilance for suppurative complications is warranted, and a lower threshold for clinical re-assessment is appropriate.
Red Flags — When to Seek Urgent Care
Parents and caregivers should seek immediate medical attention if a child with sore throat develops any of the following:
- Difficulty breathing or stridor — may indicate severe tonsillar hypertrophy, retropharyngeal abscess, or epiglottitis.
- Inability to swallow saliva (drooling) — suggests significant airway or pharyngeal compromise.
- "Hot potato" or muffled voice — classic sign of peritonsillar abscess, which requires drainage.
- Trismus (difficulty opening the mouth) — another indicator of peritonsillar or deep neck space infection.
- Neck swelling with toxicity — diffuse neck swelling with high fever and systemic toxicity may indicate Lemierre syndrome or deep neck space abscess.
- Persistent fever >48–72 hours on antibiotics — warrants re-evaluation for complications or alternative diagnoses.
- Scarlatiniform rash — while not dangerous in itself (scarlet fever is simply GAS pharyngitis with a toxin-mediated rash), it confirms GAS etiology and warrants antibiotic treatment if not already initiated.
- Dark or cola-colored urine 1–3 weeks after pharyngitis — may indicate post-streptococcal glomerulonephritis; requires prompt evaluation.
Frequently Asked Questions
1. Can my child go to school while on antibiotics for strep throat?
Children with confirmed GAS pharyngitis may return to school after at least 12–24 hours of appropriate antibiotic therapy and once they are afebrile, per AAP and CDC guidance. This window allows sufficient antibiotic exposure to substantially reduce transmissibility.
2. My child's strep test was positive but they feel fine — should I still give antibiotics?
If the RADT or culture was obtained during a symptomatic episode and is positive, treatment is appropriate even if symptoms are mild. However, if the child was asymptomatic at the time of testing (e.g., tested as a household contact), the positive result likely reflects the carrier state, and treatment is generally not indicated unless specific risk factors for ARF are present.
3. Is azithromycin (Zithromax) just as good as amoxicillin for strep throat?
No. Azithromycin is a second-line agent reserved for children with documented penicillin allergy. GAS resistance to macrolides (including azithromycin) has been reported at 5–15% in some regions, and bacteriological failure rates are higher compared with penicillin or amoxicillin. It should not be used as a first choice simply for convenience of a shorter course.
4. What if my child vomits the antibiotic within 30 minutes of taking it?
If vomiting occurs within approximately 30 minutes of dosing, repeat the full dose. If vomiting is recurrent and oral therapy is not feasible, contact the prescribing clinician — a single intramuscular injection of penicillin G benzathine may be a practical alternative to complete the treatment course.
5. Do I need a follow-up strep test after finishing antibiotics?
Routine post-treatment testing (test-of-cure) is not recommended for asymptomatic children. A positive follow-up culture in an asymptomatic child most likely represents the carrier state and does not require additional treatment. Test-of-cure may be considered in specific high-risk situations, such as a personal history of rheumatic fever.
6. Can strep throat go away on its own without antibiotics?
GAS pharyngitis is typically self-limited — symptoms resolve in 3–5 days even without antibiotics. However, antibiotic treatment is recommended to prevent rheumatic fever (which can be initiated up to 9 days after symptom onset and still be protective), reduce suppurative complications, shorten symptom duration by approximately 1–2 days, and reduce transmission to contacts.
7. My child keeps getting strep throat — is tonsillectomy the answer?
Tonsillectomy may be considered for children with recurrent, culture-confirmed episodes meeting specific frequency thresholds (the Paradise criteria). However, episode frequency typically decreases naturally as children age, and tonsillectomy carries surgical risks including pain, bleeding, and a small risk of serious complications. The decision should be individualized in consultation with an otolaryngologist.
8. Is it strep if my child also has a cough and runny nose?
Cough and rhinorrhea strongly suggest a viral etiology. The IDSA guideline specifically lists cough, coryza, conjunctivitis, hoarseness, and oral ulcers as features that make GAS pharyngitis unlikely. Testing for GAS is generally not recommended when these symptoms predominate.
References
-
Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86–e102. PMID: 22965026
-
Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association. Circulation. 2009;119(11):1541–1551. PMID: 19246689
-
NICE. Sore throat (acute): antimicrobial prescribing. Guideline NG84. 2018. nice.org.uk/guidance/ng84
-
Spinks A, Glasziou PP, Del Mar CB. Antibiotics for treatment of sore throat in children and adults. Cochrane Database Syst Rev. 2013;(11):CD000023. PMID: 24190439
-
Wessels MR. Streptococcal pharyngitis. N Engl J Med. 2011;364(7):648–655. PMID: 21323542
-
Choby BA. Diagnosis and treatment of streptococcal pharyngitis. Am Fam Physician. 2009;79(5):383–390. PMID: 19275067
-
AAP Committee on Infectious Diseases. Red Book: 2021–2024 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021. aap.org/redbook
-
CDC. Group A streptococcal pharyngitis: clinical guidance for healthcare professionals. 2024. cdc.gov/group-a-strep
-
DailyMed. Amoxicillin — drug label information. National Library of Medicine. dailymed.nlm.nih.gov
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in evidence-based pharmacotherapy. He has practiced in hospital, ambulatory, and community pharmacy settings, with particular expertise in pediatric and infectious disease therapeutics. Dr. Ozarchuk contributes to PillsCard.com as a medical writer and clinical reviewer, translating primary-source evidence and guideline recommendations into accessible content for patients and healthcare providers worldwide.
Medical Disclaimer
This article is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The dosing information presented reflects published guidelines current at the time of writing but may not account for individual patient factors, local resistance patterns, or formulary considerations. Always consult a qualified healthcare provider — such as your child's pediatrician or pharmacist — before starting, stopping, or changing any medication. Do not delay seeking professional medical advice because of information read on this website. In the event of a medical emergency, contact your local emergency services immediately. PillsCard.com and its contributors assume no liability for actions taken based on the content of this article.